MA-AURIGENE
Aurigene:
SITC – Nov 7-11, Washington D.C.:
(a)
CA-170 - Small molecule oral antagonist of PD-L1/VISTA in
Ph-2 (India)
(b)
Small molecule oral antagonist of
CD47
(c)
Small molecule oral antagonist of TIGIT/PD-L1
EORTC-NCI-AACR – Nov 13-16, Dublin:
a.
Covalent, highly selective CDK12 inhibitors
b.
Degrader of SMARCA2/4
c.
Dual antagonists of TIGIT
and PD-1 pathways
d.
Dual inhibitors of CD73 and A2AR
Details: SITC, Nov 7-11 Washington D.C.
CA-170 Small Molecule Oral Antagonist
Targeting PD-L1/VISTA
Title: Phase 2 trial of
CA-170, a novel oral small molecule dual inhibitor of immune checkpoints
VISTA and PD-1, in patients with advanced solid tumor and Hodgkin
lymphoma
Abstract Number: P714
Session Details: Late
Breaking
Date & Location: Friday, Nov. 9 from 8 a.m. to 8 p.m. and
Saturday, Nov. 10 from 8 a.m. to 8:30 p.m. Hall. E
Small Molecule Oral Antagonist Targeting CD47
Title:
Efficacy and safety profile of AU7R-104, a small molecule targeting
CD47/SIRPα pathway
Abstract Number: P529
Session
Details: Innate Anti-Tumor Immunity (NK cells, monocytes, macrophages,
etc.)
Date & Location: Friday, Nov. 9, from 12:45 – 2:15 p.m. and
6:30 – 8 p.m. Hall E
Small Molecule Oral Antagonist Targeting
TIGIT/PD-L1 Pathways
Title: An orally
bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways
shows immune-mediated anti-tumor activity
Abstract Number:
P694
Session Details: T-cell Checkpoints and Checkpoint Inhibitors
Date
& location: Saturday, Nov. 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30
p.m. Hall E
More details: https://www.sitcancer.org/2018/abstracts/titles
Details of Poster Presentations at EORTC-NCI-AACR, Nov 13-16, Dublin
Covalent Selective CDK12 Inhibitors
Title:
Potent anti-tumor activity correlated with inhibition of DNA damage
response genes with highly selective and orally bioavailable CDK12
covalent inhibitors
Poster Session:
"Drug Design" on
15 November 2018
Poster Time:
Thursday 15 November:
10.00-17.30
Poster Abstract Number:
280
Poster Board
Number:
PB041
SMARCA2/4 Degraders
Title:
In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
Poster
Session:
"Molecular Targeted Agents - PART II" on 16 November 2018
Poster
Time:
Friday 16 November: 10.00-14.00
Poster Abstract Number:
411
Poster Board Number:
PB074
Small Molecule Oral Antagonists Targeting
TIGIT/PD-L1 Pathways
Title: Oral immune
checkpoint antagonists dually targeting TIGIT and PD-1 pathways for
cancer therapy
Poster Session:
"Immune Checkpoints"
on 14 November 2018
Poster Time:
Wednesday 14 November:
10:00-17:30
Poster
Abstract Number:
230
Poster Board Number:
PB081
Dual Inhibitors of CD73 and A2AR
Title:
First-in-class dual inhibitors of CD73 and A2AR for effective
suppression of the adenosine signaling pathway to improve anti-tumor
immunity
Poster Session:
"Late Breaking Poster
Presentation" on 13-16 November 2018
Poster Time:
Tuesday 13 November: 12.00-18.30; Wednesday 14 November: 10.00-17.30;
Thursday
15 November: 10.00-17.30; Friday 16 November: 10.00-14.00
Poster
Abstract Number:
LBA17
Poster Board Number:
PB220
More details: https://www.ecco-org.eu/Events/ENA2018/Scientific-Programme-and-Abstracts
About Aurigene
Aurigene’s
Proprietary Programs business is engaged in discovery and clinical
development of novel and best-in-class therapies to treat cancer and
inflammatory diseases. Aurigene’s pipeline is focused on oral
check-point inhibitors, transcriptional CDK inhibitors (CDK7 and CDK12)
and protein degraders focused on the chromatin remodeling complex
(including SMARCA2/4 degraders). Aurigene’s oral PD-L1/ VISTA antagonist
program is currently in Phase 2 (trial initiated by Aurigene in India).
Aurigene has initiated a Phase I study for its RORg program for
autoimmune diseases in July 2018 and expects to initiate Phase 2 studies
by early 2019. Aurigene’s selective CDK7 inhibitor is slated for an IND
by Q1 2019 and CDK12 inhibitor by end-2019. More details of our pipeline
can be found at: http://www.aurigene.com/proprietary-programs/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005435/en/
Contact:
Aurigene Rajshree KT Senior Director Strategic Alliances +91–40–44657777 pr@aurigene.com
Link:
Social Media:
https://www.facebook.com/Aurigene-Discovery-Technologies-152736071453990/?fref=ts&ref=br_tf
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
E4LIFE19.4.2024 17:14:35 CEST | Press release
“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%
CA-QUALCOMM-INCORPORATED19.4.2024 15:01:33 CEST | Press release
Qualcomm Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call
CO-NEWMONT-CORPORATION19.4.2024 14:57:33 CEST | Press release
Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer
TX-SLB19.4.2024 12:51:33 CEST | Press release
SLB Announces First-Quarter 2024 Results, Targeting to Return $7 Billion to Shareholders Over 2024–2025
CO-ZAYO-GROUP19.4.2024 09:01:30 CEST | Press release
Zayo Group Appoints New CEO of Zayo Europe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom